BioCentury
ARTICLE | Company News

Jazz Pharmaceuticals, Aytu deal

July 27, 2015 7:00 AM UTC

Aytu purchased ProstaScint from Jazz for $1.7 million up front. Aytu will pay Jazz 8% of net sales after Oct. 31, 2017, up to a maximum aggregate of $2.5 million. The radiolabeled mAb that recognizes...